18F-PSMA-1007 PET/CT与多参数MRI对前列腺肿瘤三维空间定位及体积估算的比较
基于验证性配对队列Next Generation Trial(NCT05141760)的134例根治性前列腺切除术前患者,18F-PSMA-1007 PET/CT在肿瘤正确空间定位(186[65.0%] vs 134[46.9%],p<0.001)和体积估算(R²=0.545 vs 0.431,p<0.001)上均优于MRI。作者认为这些发现支持在局限性前列腺癌根治性治疗前使用18F-PSMA-1007 PET/CT。
要点
- 18F-PSMA-1007 PET/CT对前列腺肿瘤正确空间定位优于MRI(186[65.0%] vs 134[46.9%],p<0.001)。
- 18F-PSMA-1007 PET/CT肿瘤体积估算优于MRI(R²=0.545 vs 0.431,p<0.001)。
- 肿瘤体积较大及Gleason分级分组≥3与两种影像正确定位相关。
核心结论
- 18F-PSMA-1007 PET/CT在确定前列腺肿瘤三维空间定位和体积方面优于MRI。
- 作者认为这些发现支持在局限性前列腺癌根治性治疗前使用18F-PSMA-1007 PET/CT。
研究设计与样本
- 验证性配对队列Next Generation Trial(NCT05141760)中134例参与者于根治性前列腺切除术前接受18F-PSMA-1007 PET/CT和MRI。
- MRI、18F-PSMA-1007 PET/CT和最终病理分别由盲法放射科医师、核医学医师和病理科医师独立评估。
- 单个肿瘤结节测量三个维度并按PI-RADSv2.1认知配准至38分区前列腺示意图。
- 正确空间定位比较采用McNemar检验,肿瘤体积估算比较采用线性回归和偏F检验。
主要发现
- 最终组织病理学识别出286个肿瘤结节。
- 18F-PSMA-1007 PET/CT正确空间定位优于MRI(186[65.0%] vs 134[46.9%],p<0.001)。
- 18F-PSMA-1007 PET/CT肿瘤体积估算优于MRI(R²=0.545 vs 0.431,p<0.001)。
- 肿瘤体积较大与18F-PSMA-1007 PET/CT正确定位相关(OR=2.05,p<0.001),≥GGG3亦相关(OR=4.92,p<0.01)。
- 肿瘤体积较大与MRI正确定位相关(OR=1.81,p<0.001),≥GGG3亦相关(OR=11.67,p<0.001)。
临床怎么用
- 作者认为这些发现支持在局限性前列腺癌根治性治疗前使用18F-PSMA-1007 PET/CT。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Fluorine-18 prostate-specific membrane antigen-1007 positron emission tomography/computed tomography (18F-PSMA-1007 PET/CT) has been shown to be superior to multiparametric magnetic resonance imaging (MRI) for the locoregional staging of intermediate-risk and high-risk prostate tumors. This study aims to evaluate whether it is also superior in estimating tumor parameters, such as three-dimensional spatial localization and volume. METHODS: 134 participants underwent 18F-PSMA-1007 PET/CT and MRI prior to radical prostatectomy as part of the validating paired-cohort Next Generation Trial (NCT05141760). MRI, 18F-PSMA-1007 PET/CT, and final pathology were independently assessed by blinded radiologists, nuclear medicine physicians, and pathologists, respectively. Individual tumor nodules were measured in three dimensions and cognitively registered to 38 segment prostate diagrams as per PI-RADSv2.1. Correct spatial localization was compared using McNemar test and estimation of tumor volumes were compared using linear regression and partial F-test. RESULTS: 286 tumor nodules were identified by final histopathology. 18F-PSMA-1007 PET/CT was superior to MRI for correct localization (186 [65.0%] vs 134 [46.9%], p < 0.001) and tumor volume estimation (R2 = 0.545 vs 0.431, p < 0.001). Larger tumors and higher Gleason Grade Group (GGG) were associated with correct localization by 18F-PSMA-1007 PET/CT (OR = 2.05, p < 0.001 for tumor volume and OR = 4.92, p < 0.01 for ≥ GGG3) and MRI (OR = 1.81, p < 0.001 for tumor volume and OR = 11.67, p < 0.001 for ≥ GGG3). CONCLUSION: 18F-PSMA-1007 PET/CT outperforms MRI for determination of three-dimensional spatial localization and volume of prostate tumors. These findings support the use of 18F-PSMA-1007 PET/CT prior to definitive treatment of localized prostate cancers.
引用
- Huang G, Albers P, Mookerji N, et al. Three-dimensional spatial localization and volume estimation of prostate tumors using 18F-PSMA-1007 PET/CT versus multiparametric MRI. Eur J Nucl Med Mol Imaging. 2024. PMID: 39725694. doi:10.1007/s00259-024-07021-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。